Literature DB >> 10672828

Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus.

J Nilsson1, V Skobe, J Johansson, R Willén, F Johnsson.   

Abstract

BACKGROUND: Screening patients with columnar metaplasia of the oesophagus for adenocarcinoma is controversial owing to the low cancer incidence and diverging opinions as to whether screening improves the prognosis of these patients. Our aim was to evaluate a screening program for adenocarcinoma in patients with columnar metaplasia in the oesophagus, with focus on cancer incidence and costs.
METHODS: One hundred and ninety-nine patients with columnar metaplasia of the oesophagus were identified through an endoscopy database, and the original patient records were reviewed.
RESULTS: The patients were followed up for 797 years in total and during this time were subjected to 1071 upper gastrointestinal endoscopies. During the screening period 5 patients presented with adenocarcinoma; thus the cancer-incidence was 1 in 159 patient-years. The cost of detecting one cancer was 294,950 SEK (US$ 37,815). However, only four of the five patients were suitable for oesophagectomy, and of these, one patient turned out to have an advanced cancer. All patients developing cancer had columnar metaplasia of the oesophagus longer than 3 cm and specialized columnar epithelium (intestinal metaplasia/Barrett oesophagus).
CONCLUSIONS: Low cancer incidence, high costs, and the doubtful prognosis for the patients with identified cancer question the benefits and cost-effectiveness of cancer screening among patients with columnar metaplasia in the oesophagus.

Entities:  

Mesh:

Year:  2000        PMID: 10672828

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Surveillance for Barrett's oesophagus. The conundrum of Barrett's oesophagus is changing.

Authors:  J A Eksteen; J A Jankowski
Journal:  BMJ       Date:  2001-05-05

2.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Antagonist: endoscopic surveillance of patients with Barrett's oesophagus.

Authors:  R J Playford
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

4.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

5.  Surveillance in Patients With Barrett's Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Yao Qiao; Ayaz Hyder; Sandy J Bae; Wasifa Zarin; Tyler J O'Neill; Norman E Marcon; Lincoln Stein; Hla-Hla Thein
Journal:  Clin Transl Gastroenterol       Date:  2015-12-10       Impact factor: 4.488

6.  Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma.

Authors:  S H Doak; G J S Jenkins; E M Parry; A P Griffiths; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

7.  Acetic acid-guided biopsies in Barrett's surveillance for neoplasia detection versus non-targeted biopsies (Seattle protocol): A feasibility study for a randomized tandem endoscopy trial. The ABBA study.

Authors:  Fergus Chedgy; Carole Fogg; Kesavan Kandiah; Hugh Barr; Bernard Higgins; Mimi McCord; Ann Dewey; John De Caestecker; Lisa Gadeke; Clive Stokes; David Poller; Gaius Longcroft-Wheaton; Pradeep Bhandari
Journal:  Endosc Int Open       Date:  2018-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.